- Home
- DEC vs BBNX Comparison
DEC vs BBNX Comparison
Compare DEC & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DEC | BBNX |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | DEC | BBNX |
|---|---|---|
| Price | $14.31 | $31.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $22.67 | ★ $28.55 |
| AVG Volume (30 Days) | 645.7K | ★ 1.0M |
| Earning Date | 03-20-2026 | 10-28-2025 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,148,432,000.00 | $88,570,000.00 |
| Revenue This Year | $126.94 | $52.13 |
| Revenue Next Year | N/A | $36.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 64.19 | ★ 67.01 |
| 52 Week Low | $10.08 | $8.89 |
| 52 Week High | $17.70 | $32.71 |
Technical Indicators
Market Signals| Indicator | DEC | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 63.34 |
| Support Level | $13.72 | $28.59 |
| Resistance Level | $14.54 | $32.26 |
| Average True Range (ATR) | 0.45 | 1.67 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 30.83 | 86.01 |
Price Performance
Historical ComparisonAbout DEC Diversified Energy Company plc
Diversified Energy Co is an independent energy company focused on natural gas and liquids production, transportation, marketing and well retirement, located within the Appalachian and Central regions of the United States. Its principal focus is on enhancing producing wells, not drilling new wells, thereby allowing it to optimise PDP revenues and reduce costs. The company derives revenues from the sale of oil, natural gas and natural gas liquids.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.